Home

Our Approach

Our proprietary, highly targeted antibody drug conjugates (ADCs) are armed with highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells.

Learn More ButtonLearn More Button

Pipeline

The selective targeting and unique mechanism of action of our ADCs enables the potential for our robust pipeline of therapies to have enhanced, durable efficacy and limited side effects in patients.

View Pipeline ButtonPipeline View Button

Clinical Trials

We are advancing our ADCs through clinical trials in multiple hematological and solid tumor indications, including a pivotal Phase II trial of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma.

Find Out More ButtonFind Out More Button

News

ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting

ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
Data on 52 patients in the 145-patient clinical trial highlight ADCT-402 (loncastuximab tesirine) continues to demonstrate anti-tumor activity and manageable toxicity in heavily pretreated patients Biologics License Application submission planned for 2H 2020   Lausanne, Switzerland, December 9, 2019 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent antibody

ADC Therapeutics Announces Presentations at 61st American Society of Hematology (ASH) Annual Meeting

ADC Therapeutics Announces Presentations at 61st American Society of Hematology (ASH) Annual Meeting
Presentations highlight lead product candidate ADCT-402 as a single agent and in combination with checkpoint inhibitor durvalumab for relapsed or refractory B-cell non-Hodgkin lymphomas Updated interim data from pivotal Phase 2 clinical trial of ADCT-402 selected for oral presentation Company to host investor event on Sunday, December 8   Lausanne, Switzerland, November 6, 2019 –

ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer

ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer
Biopharma leader with deep oncology product launch experience will spearhead global commercial strategy and execution for ADCT-402   Lausanne, Switzerland, November 5, 2019 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced the appointment